Alcohols, C10-16, ethoxylated, sulfates, triethanolammonium salts

Endpoint summary

Description of key information

No data are available for the target substance Alcohols, C12-14, ethoxylated (1-2.5 EO), sulfates, triethanolammonium salts (CAS 157627-94-6). Therefore, read-across from structural analogue substances has been applied.

Oral LD50 (OECD 401), rat > 2000 mg/kg bw

Read-across from structural analogue source substance Alcohols, C12-14, ethoxylated, sulfates, sodium salts (CAS 68891-38-3).

Dermal LD50 (OECD 406), rat > 2000 mg/kg bw (limit test)

Read-across from structural analogue source substances Fatty alcohol ether sulfate, sodium salt, C8-10 2EO, Fatty alcohol C12-C14, ethoxylated (2 EO) sulphated sodium salt (CAS 68891-38-3), AES (C12-14; 2 EO) TIPA (CAS 174450-50-1) and AES (C12-13) NH4 (CAS 68585-34-2).

Acute toxicity by inhalation was not tested according to REGULATION (EC) No 1907/2006, Annex VIII, Section 8.5, Column 2.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Reference 1

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

guideline study with acceptable restrictions

Remarks:

Only limited information on the test material are available.

Qualifier:

according to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Deviations:

no

GLP compliance:

no

Test type:

standard acute method

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

According to Guideline.

Route of administration:

oral: gavage

Vehicle:

unchanged (no vehicle)

Doses:

2000, 3200, 4000, 5000 mg/kg bw

No. of animals per sex per dose:

5

Control animals:

no

Sex:

male/female

Dose descriptor:

LD50

Effect level:

4 100 mg/kg bw

Based on:

test mat.

Sex:

male/female

Dose descriptor:

LD50

Effect level:

2 870 mg/kg bw

Based on:

act. ingr.

Mortality:

There were deaths among animals dosed at 4000 and 5000 mg/kg bw.

Clinical signs:

other: Signs of reaction to treatment observed in all rats that survived for more than one hour after dosing were piloerection, hunched posture, abnormal gait (waddling), lethargy and diarrhoea. These were accompanied by: - decreased respiratory rate and pallor

Gross pathology:

No effects.

Interpretation of results:

other: CLP/EU GHS criteria not met, no classification required according to Regulation (EC) No 1272/2008.

Reference 2

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

supporting study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

standard acute method

Limit test:

yes

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

According to Guideline.

Route of administration:

oral: gavage

Vehicle:

unchanged (no vehicle)

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

5

Control animals:

no

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

No deaths.

Clinical signs:

other: The animals showed mild clinical signs (increased activity and piloerection) as a reaction for treatment for about 4 hours after dosing.

Gross pathology:

No effects.

Interpretation of results:

other: CLP/EU GHS criteria not met, no classification required according to Regulation (EC) No 1272/2008.

Endpoint conclusion

Endpoint conclusion:

adverse effect observed

Dose descriptor:

LD50

Value:

2 000 mg/kg bw

Quality of whole database:

The whole data base is conclusive and sufficient for assessment of the acute oral toxicity potential of the target substance.

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no study available

Quality of whole database:

Acute toxicity by inhalation was not tested according to Regulation (EC) No. 1907/2006, Annex VIII, Section 8.5, Column 2.

Acute toxicity: via dermal route

Link to relevant study records

Reference

Reference 1

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

weight of evidence

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

standard acute method

Limit test:

yes

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

According to Guideline.

Type of coverage:

semiocclusive

Vehicle:

unchanged (no vehicle)

Duration of exposure:

24 h

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

5

Control animals:

not required

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Mortality:

No effects.

Clinical signs:

other: No systemic effects.

Gross pathology:

No effects.

Other findings:

Moderate to severe dermal irritations at the treatment site were observed following removal of the dressings. 24 h after dermal application of the test substance four male and three female animals showed inflammation of the treated skin. One male and two females showed no skin lesions.
48 h after application an induration of the skin lesions occured and 72 h after application a scab formation was noticed. The scab was fallen off 6 days later in male animals and 12 days later in female animals. On day 14 only one female animal showed residual scabs and a slightly scarred skin.

Interpretation of results:

other: CLP/EU GHS criteria not met, no classification required according to Regulation (EC) No 1272/2008.

Reference 2

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

weight of evidence

Study period:

29 Dec 1977 - 13 Feb 1978

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

guideline study with acceptable restrictions

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Deviations:

yes

Remarks:

- 3 males and 3 females were dosed for each test substance instead of 5 males and 5 females

GLP compliance:

no

Test type:

standard acute method

Limit test:

yes

Species:

rabbit

Strain:

New Zealand White

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Isaacs lab stock
- Weight at study initiation: males 2.1 - 2.8 kg and females 2.3 - 3 kg.
-- Housing: Individually in stainless cages with stainless steel slatted flooring
- Diet: Purina lab rabbit chow, ad libitum
- Water: Tap water, ad libitum
- Acclimation period: 7 days minimum

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.5 to 20.5°C
- Photoperiod (hrs dark / hrs light): 12 hours on/off flurescent lighting

IN-LIFE DATES: From: 1977-12-29 To: 1978-02-13

Type of coverage:

occlusive

Vehicle:

unchanged (no vehicle)

Details on dermal exposure:

TEST SITE
- Area of exposure: Backs of animals (Intact and Abraded skin sites)
- % coverage: Test site covered with 8 ply gauze
- Type of wrap if used: Saran wrap and elastoplast tape

REMOVAL OF TEST SUBSTANCE
- Washing (if done): Test areas were wiped with a wet paper towel
- Time after start of exposure: 24 hours

TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg bw (2 mL/kg bw)
- Concentration (if solution): Undiluted
- Constant volume or concentration used: yes

Duration of exposure:

24 h

Doses:

2000 mg/kg bw for each test substance

No. of animals per sex per dose:

3 male and 3 female animals for each test substance (3 animals - intact, 3 animals - abraded)

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observation - daily for 14 days post administration; Weighing - Initial and final
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Remarks on result:

other: For both P0304 and P0305 (60% each)

Mortality:

No mortality was observed.

Clinical signs:

other: P0304 (NH4C12 -13AE3S/ Shell shop) – Erythema was observed on all animals on day 1 and persisted on 3 of 6 for the full 14 days. Oedema was observed only on day 3 and only on 2 of 6 animals. Atonia was observed on all animals beginning on day 3. Eschar de

Gross pathology:

Necropsy results for both groups (P0304 and P0305) were not remarkable.

Other findings:

- Organ weights: None
- Histopathology: None
- Potential target organs: None
- Other observations: None

Interpretation of results:

other: CLP/EU GHS criteria not met, no classification required according to Regulation (EC) No 1272/2008.

Conclusions:

The dermal LD50 for both P0304 (60% active NH4C12 -13AE3S) and P0305 (60% active NH4C12 -13AE3S) is > 2000 mg/kg bw. Thus, for both test substances no classification is warranted.

Reference 3

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

weight of evidence

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

guideline study with acceptable restrictions

Qualifier:

according to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Deviations:

yes

Remarks:

Occlusive dressing.

GLP compliance:

yes

Test type:

standard acute method

Limit test:

yes

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

According to Guideline.

Type of coverage:

occlusive

Vehicle:

unchanged (no vehicle)

Duration of exposure:

24 h

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

5

Control animals:

not required

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Mortality:

No effects.

Clinical signs:

other: No systemic effects.

Gross pathology:

No effects.

Interpretation of results:

other: CLP/EU GHS criteria not met, no classification required according to Regulation (EC) No 1272/2008.

Reference 4

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

weight of evidence

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Version / remarks:

(1987)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Remarks:

Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit

Test type:

fixed dose procedure

Limit test:

yes

Species:

rat

Strain:

other: WISTAR rats Crl: WI(Han)

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River, 97633 Sulzfeld, Germany
- Age at study initiation: males: 7-8 weeks, females: 11-12 weeks
- Weight at study initiation: males: 221 – 235 g, females: 212 – 229 g.
- Diet: Altromin 1324 maintenance diet for rats and mice (lot no. 0939), ad libitum
- Water: tap water, sulphur acidified to a pH value of approximately 2.8, ad libitum
- Acclimation period: at least five days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 55 ± 10
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12/12

Type of coverage:

semiocclusive

Vehicle:

unchanged (no vehicle)

Details on dermal exposure:

TEST SITE
- Area of exposure: approx. 10%
REMOVAL OF TEST SUBSTANCE
- Washing: The residual test item was removed using aqua ad injectionem
- Time after start of exposure: 24 h

Duration of exposure:

24 h

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: A careful clinical examination was made several times on the day of dosing. Thereafter, the animals were observed for clinical signs once daily. The animals were weighed on day 1 (prior to the application) and on days 8 and 15.
- Necropsy of survivors performed: yes

Sex:

male/female

Dose descriptor:

LD50

Effect level:

>= 2 000 mg/kg bw

Based on:

test mat.

Remarks on result:

other: No mortality occurred.

Mortality:

No mortality occurred.

Clinical signs:

other: No clinical signs of toxicity occurred. Signs of dermal irritation were observed. Erythema grade 1 was observed on 10/10 animals on day 4 which was fully reversed on day 5 on all animals. Eschar formation was observed from day 4 to day 8 and desquamation

Gross pathology:

Upon gross pathology hernia (liver) into the diaphragm was observed in one female. This incidental finding is not considered to be treatment related.

Table 1: Absolute Body Weights in g and Body Weight Gain in %

Animal No. / Sex	Day 1	Day 8	Day 15	Day 1-15
21 / male	226 g	241 g	282 g	25 %
22 / male	231 g	250 g	292 g	26 %
23 / male	230 g	238 g	274 g	19 %
24 / male	221 g	236 g	270 g	22 %
25 / male	235 g	245 g	282 g	20 %
Mean ± SD	229 ± 5.3 g	242 ± 5.6 g	280 ± 8.5 g	22 ± 3.0 %
26 / female	213 g	215 g	220 g	3 %
27 / female	216 g	213 g	217 g	0 %
28 / female	212 g	205 g	216 g	2 %
29 / female	229 g	227 g	250 g	9 %
30 / female	217 g	223 g	234 g	8 %
Mean ± SD	217 ± 6.8 g	217 ± 8.6 g	227 ± 14.6 g	4 ± 3.9 %

Interpretation of results:

other: CLP/EU GHS criteria not met, no classification required according to Regulation (EC) No 1272/2008.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

2 000 mg/kg bw

Quality of whole database:

The whole data base is conclusive and sufficient for assessment of the acute dermal toxicity potential of the target substance by a WoE approach.

Additional information

No data on acute toxicity are available for AES (C12-14; 1-2.5 EO) C6H15NO3 (CAS 157627-94-6). Therefore this endpoint is covered by read-across from structurally related AES. The AES reported within the category show similar structural, physico-chemical, environmental and toxicological properties. The approach of grouping different AES for the evaluation of their effects on human health and the environment was also made by the Danish EPA (2001) and HERA (2003), supporting the read-across approach between structurally related AES.

Acute toxicity: oral

There are two studies available addressing acute oral toxicity for the read-across substances AES (C12-14; 1-2.5 EO) Na (CAS 68891-38-3) and AES (C12-14; 1-2.5EO) TIPA (CAS 174450-50-1).

The key study conducted with AES (C12-14; 2 EO) Na (CAS 68891-38-3) was performed according to OECD Guideline 401 on five Sprague-Dawley rats per sex and dose (Unger Fabrikker, 1986a). Both sexes were dosed with the test substance (analytical purity 70%) at 2000, 3200, 4000 and 5000 mg/kg bw via gavage. Mortalities occurred at the highest dose levels of 4000 and 5000 mg/kg, resulting in a LD50 of 4100 mg/kg bw for males and females based on the test material. Based on the active ingredient the LD50 is 2870 mg/kg bw for males and females. Upon gross pathology no effects were observed.

A further supporting study regarding acute oral toxicity was conducted on five Wistar rats per sex and dose with AES (C12-14; 2 EO) TIPA (CAS 174450-50-1) according to OECD Guideline 401 (Sasol, 1997a). Both sexes were dosed with the test substance at the limit dose of 2000 mg/kg bw via gavage. No mortalities occurred. The only effects observed were increased activity and piloerection for about 4 hours after dosing as a reaction on treatment. Hence, the LD50 was determined to be greater than 2000 mg/kg bw.

Acute toxicity: dermal

Regarding the acute dermal toxicity four studies are available from the analogue substances AES (C12-14; 1-2.5 EO) Na (CAS 68891-38-3), AES (C12-14; 1-2.5 EO) TIPA (CAS 174450-50-1), AES (C12-13) NH4 and AES (C8-10; 1-2.5 EO) Na. These are considered in a Weight-of-Evidence approach.

The study conducted with AES (C12-14) Na (CAS 68891-38-3) was performed as limit test conducted according to OECD Guideline 402 with five Wistar rats per sex (Z&S, 1989). The test substance (analytical purity 27%) was applied at 2000 mg/kg bw for 24 h under occlusive conditions. No mortalities and no clinical signs of toxicity occurred. Hence, the LD50 value is greater than 2000 mg/kg bw based on the test material and greater than 540 mg/kg bw based on the active ingredient.

The study conducted with AES (C12-14; 2 EO) TIPA (CAS 174450-50-1, analytical purity 83.8%) was performed as limit test conducted according to OECD Guideline 402 with five Wistar rats per sex (Sasol, 1997). The test substance was applied at 2000 mg/kg bw for 24 h under semi-occlusive conditions. No mortalities and no clinical signs of toxicity occurred. Findings within this study comprised of local signs of irritation at the application site. Hence, the LD50 value is greater than 2000 mg/kg bw based on the test material.

With AES (C12-13) NH4 (CAS 68585-34-2), a non-GLP study similar to OECD Guideline 402 was carried out on three male and three female New Zealand White rabbits (P&G, 1978a). Both sexes were dosed at 2000 mg/kg bw (analytical purity 60%) under occlusive conditions for 24 h. No mortalities occurred during the conduct of the study. Findings within this study comprised of local signs of irritation at the application site. Based on the above mentioned findings the LD50 is greater than 2000 mg/kg bw based on the test material and greater than 1200 mg/kg bw based on the active ingredient.

The study with AES (C8-10; 1-2.5 EO) Na was conducted according to OECD Guideline 402 as a limit test at 2000 mg/kg bw on five Wistar rats per sex (Z&S, 2012). The pure test substance was applied for 24 h under semi occlusive conditions. No mortalities and no clinical signs of toxicity occurred. Hence, the LD50 value is greater than 2000 mg/kg bw. Signs of dermal irritation were observed. Erythema grade 1 was observed on 10/10 animals on Day 4 which was fully reversed on Day 5 on all animals. Eschar formation was observed from Day 4 to 8 and desquamation was observed beginning on Day 6 (10/10 animals both). Desquamation was observed in 7/10 animals until study termination. Scratches were observed in 2 of 5 females. Upon gross pathology hernia (liver) into the diaphragm was observed in one female. This incidental finding is not considered to be treatment related. A further incidental finding was a decreased body weight of 3/5 females after one week. As the females gained weight thereafter and no effect on body weight was observed for males this finding is of no toxicological relevance.

Acute toxicity: inhalation

No studies for acute inhalation toxicity are available. However, testing the potential of acute toxicity via inhalation route of AES (C12-14) is considered to be not justified. According to Regulation (EC) No. 1907/2006, Annex VIII, Section 8.5, Column 2, in addition to the oral route (8.5.1), for substances other than gases, the information mentioned under 8.5.2 to 8.5.3 shall be provided for at least one other route, i.e, for the inhalation or the dermal route. As information under 8.5.3 (dermal route) is provided, the requirement is fulfilled by using the most appropriate route of exposure. As information is available with respect to the dermal route, the requirement is considered fulfilled by the most appropriate route of exposure. In fact, AES is mainly used in liquid media and due to its very low vapour pressure (HERA (2003)) inhalation is not viewed as a significant route of exposure. Inhalation of AES may occur by exposure to aerosols generated by spray cleaners or by inhalation of detergent dusts (e.g. washing powder). Taken into account that the acute toxicity of AES is generally low no further information on acute toxicity is expected by testing for acute inhalation toxicity.

Influence of counter ions on acute toxicity

Since triethanolamine (TEA) in its protonated form (triethanolammonium) is the counter-ion present in Alcohols C12-14, ethoxylated (1-2,5 EO) sulphated, trieth salts (CAS 157627-94-6), TEA might have an impact on the toxicological properties of the registered substance. Therefore, the toxicological profile of TEA is considered. TEA not listed in Annex VI of Regulation 1272/2008. In addition, the effects of TEA on human health were assessed by the OECD in the SIDS initial assessment Report (2013). Despite of some local signs of irritation TEA gives no rise to concern of adverse effects on human health. Therefore, contribution of TEA to acute toxicity is not expected. 

References:

Danish EPA - Environmental and Health Assessment of Substances in Household Detergents and Cosmetic Detergent Products (2001). Environmental Project No. 615, pp. 24-28

HERA (2003). Human & Environmental Risk Assessment on ingredients of European household cleaning products Alcohol Ethoxysulphates, Human Health Risk Assessment Draft, 2003. http: //www. heraproject. com.

SIDS initial assessment report, (2013); http://webnet.oecd.org/HPV/UI/SIDS_Details.aspx?key=8aefe41b-8499-4052-943f-f6dd6f8c5997&idx=0

Justification for classification or non-classification

The available data on relevant read-across source substances for both acute oral and acute dermal toxicity do not meet the criteria for classification according to Regulation (EC) No. 1272/2008 (CLP). Therefore, applying the read-across approach, the target substance Alcohols C12-14, ethoxylated (1-2,5 EO) sulphated, trieth salts (CAS 157627-94-6) is considered not to meet the criteria for classification for acute oral and dermal toxicity. Data are therefore conclusive but not sufficient for classification. No data regarding acute inhalation toxicity are available.